Coronado (CNDO) Initiates IIS for CNDO-201 on ASD

November 12, 2012 7:34 AM EST Send to a Friend
Coronado Biosciences, Inc. (Nasdaq: CNDO) announced the initiation of an Investigator-Initiated Study (IIS) evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of autism spectrum disorders (ASD). The study is being conducted by the Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Eric Hollander, Clinical Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine and Director of the Autism and Obsessive Compulsive Spectrum Program at Montefiore Medical Center and the Albert Einstein College of Medicine, is the Principal Investigator of the trial.

This trial is a randomized, double-blind, placebo-controlled, cross-over study designed to enroll 10 patients who meet criteria for the diagnosis of autism spectrum disorders. Patients will receive placebo or TSO for 12 weeks, with a 4 week washout and then 12 weeks of the treatment not yet received. The goal of the pilot study is to test for early safety and efficacy of TSO compared to placebo on repetitive behaviors, irritability, global functioning and social cognition in adults with ASD.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment